GBT Announces New Employment Inducement Grants
March 05 2018 - 4:05PM
Global Blood Therapeutics, Inc. (GBT or the Company)
(NASDAQ:GBT) today announced that on March 1, 2018, the
compensation committee of the Company’s board of directors granted
four new employees options to purchase an aggregate of 7,500 shares
of the Company’s common stock with a per share exercise price of
$58.80, the closing trading price on the grant date, and restricted
stock units for an aggregate of 4,950 shares of the Company’s
common stock. All of the above-described awards were made under the
Company’s 2017 Inducement Equity Plan (the "Plan").
The above-described awards were each granted as an inducement
material to the employees’ entering into employment with the
Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were
granted pursuant to the terms of the Plan. The Company has reserved
an aggregate of 300,000 shares of its common stock (including the
shares underlying the stock options and restricted stock unit
awards described above) for issuance under the Plan, which was
approved by the Company’s Board of Directors in January 2017.
About Global Blood TherapeuticsGBT is a
clinical-stage biopharmaceutical company determined to discover,
develop and deliver innovative treatments that provide hope to
underserved patient communities. GBT is developing its lead product
candidate, voxelotor, as an oral, once-daily therapy for sickle
cell disease. To learn more, please visit www.gbt.com and follow
the company on Twitter @GBT_news.
Contact Information: Myesha Lacy
(investors)GBT650-351-4730investor@gbt.com
Julie Normart (media)W2O pure 415-946-1087media@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024